Title: HOUSE BILL 1502
Official Title: HOUSE BILL 1502
Number of Sections: 1
Source: versions - First - Baltimore City - AIDS Prevention Sterile Needle and Syringe Exchange Pilot Program - Revisions
Media Type: application/pdf
Strikethrough Detection: 7 sections found

================================================================================

Section 1:
J1 5lr3585
CF 5lr3586
By: Delegate Wells (By Request – Baltimore City Administration)
Introduced and read first time: February 14, 2025
Assigned to: Rules and Executive Nominations
A BILL ENTITLED
1 AN ACT concerning
2 Baltimore City – AIDS Prevention Sterile Needle and Syringe Exchange Pilot
3 Program – Revisions
4 FOR the purpose of renaming the AIDS Prevention Sterile Needle and Syringe Exchange
5 Pilot Program to be the HIV Prevention Syringe Services Program; altering the
6 duties of the Program, the Director of the Program, and the Baltimore City Health
7 Department regarding the Program; altering the membership and duties of the
8 Program’s oversight committee; altering the immunity provided to Program staff and
9 participants; and generally relating to the AIDS Prevention Sterile Needle and
10 Syringe Exchange Pilot Program.
11 BY repealing and reenacting, without amendments,
12 Article – Health – General
13 Section 24–801(a)
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Health – General
18 Section 24–801(e), 24–802 through 24–806, 24–808, and 24–809
19 Annotated Code of Maryland
20 (2023 Replacement Volume and 2024 Supplement)
21 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
22 That the Laws of Maryland read as follows:
23 Article – Health – General
24 24–801.
25 (a) In this subtitle the following words have the meanings indicated.
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from exist in g l aw . *hb1502*
2 HOUSE BILL 1502
1 (e) “Program” means the [AIDS] HIV Prevention [Sterile Needle and] Syringe
2 [Exchange Pilot] SERVICES Program.
3 24–802.
4 (a) There is an [AIDS] HIV Prevention [Sterile Needle and] Syringe [Exchange
5 Pilot] SERVICES Program in the Baltimore City Health Department.
6 (b) The Program shall:
7 (1) [Provide] DISTRIBUTE SYRINGES AND PROVIDE for the exchange by
8 participants of used hypodermic needles and syringes for sterile hypodermic needles and
9 syringes AS NEEDED; and
10 (2) Operate in accordance with the procedures approved, with the advice
11 and approval of the oversight committee, by the Commissioner of Health.
12 24–803.
13 The Program shall:
14 (1) Be designed and maintained to provide [maximum security of exchange
15 locations and equipment, including] security measures [that may be] AND PROCESSES
16 required to [control the use and dispersal of] SAFELY DISTRIBUTE hypodermic needles
17 and syringes and [security measures that allow for a full accounting of] ACCOUNT FOR the
18 number of hypodermic needles and syringes [in circulation] EXCHANGED AND
19 DISTRIBUTED BY THE BALTIMORE CITY HEALTH DEPARTMENT and the number of
20 hypodermic needles and syringes in storage;
21 (2) Be operated to allow participants to exchange used hypodermic needles
22 and syringes at [any exchange location, if more than one location is] available MOBILE
23 SYRINGE SERVICES SITES;
24 (3) Include appropriate levels of staff expertise in working with injecting
25 drug users and adequate staff training in providing community SERVICE PROVIDER
26 referrals, counseling, and preventive education;
27 (4) Provide for the dissemination of other preventive means for [curtailing
28 the spread of the HIV infection] DECREASING THE RISK OF HIV TRANSMISSION;
29 (5) Provide [a linkage for] referrals to drug counseling and treatment
30 services, and follow–up to those referrals to assure that participants receive the treatment
31 they desire;
HOUSE BILL 1502 3
1 (6) Educate injecting drug users on the [dangers of contracting the HIV
2 infection] RISK OF TRANSMITTING HIV or the hepatitis B virus through HIGH–RISK
3 needle–sharing practices and [unsafe] sexual behaviors;
4 (7) Include policies and procedures for the screening of applicants to the
5 Program in order to preclude noninjecting drug users from participating in the Program;
6 AND
7 (8) [Establish] IMPLEMENT procedures for identifying Program
8 participants that are consistent with the confidentiality provisions of this subtitle[; and
9 (9) Establish a method of identification and authorization for Program staff
10 members who have access to hypodermic needles, syringes, or Program records].
11 24–804.
12 (a) The Mayor of Baltimore City shall appoint an oversight committee for the
13 Program.
14 (b) The oversight committee shall consist of:
15 (1) [Two representatives] ONE REPRESENTATIVE from academia who
16 [specialize] SPECIALIZES in public health issues;
17 (2) One representative from law enforcement[, nominated by the Secretary
18 of Public Safety and Correctional Services];
19 [(3) One representative of the Baltimore City Police Department;]
20 [(4)] (3) [Two representatives] ONE REPRESENTATIVE from the
21 Maryland Department of Health[, the Department of Juvenile Services, or the Department
22 of Education, nominated by the Secretary of Health];
23 [(5)] (4) One representative of a Baltimore City community group;
24 [(6)] (5) One representative of an [AIDS] HIV advocacy group;
25 [(7)] (6) One [drug abuse] ADDICTION treatment counselor;
26 [(8)] (7) One recovering injecting drug user; and
27 [(9)] (8) Up to three other individuals whom the [Mayor of Baltimore
28 City] BALTIMORE CITY HEALTH DEPARTMENT determines to be appropriate for
29 appointment to the oversight committee.
4 HOUSE BILL 1502
1 (c) The oversight committee shall:
2 (1) Provide advice to the Commissioner of Health and the Program Director
3 on developing AND REVISING AS NECESSARY:
4 (i) Program operating procedures for the [furnishing]
5 DISTRIBUTION and exchange of hypodermic needles and syringes to injecting drug users;
6 (ii) A plan for community outreach and education;
7 (iii) A protocol for providing [a linkage] REFERRALS for Program
8 participants to [substance abuse] ADDICTION treatment and rehabilitation; and
9 (iv) A plan for evaluating the Program; and
10 (2) Provide ongoing oversight of the Program and make recommendations
11 to the Program Director or the Commissioner of Health regarding any aspect of Program
12 procedures, operation, or evaluation.
13 24–805.
14 (a) The Commissioner of Health shall appoint a Director for the Program.
15 (b) With the advice [and approval] of the oversight committee, the Director shall
16 develop AND REVISE AS NECESSARY:
17 (1) Program operating procedures for the [furnishing] DISTRIBUTION and
18 exchange of hypodermic needles and syringes to injecting drug users;
19 (2) A community outreach and education program; and
20 (3) A protocol for providing [a linkage] REFERRALS for Program
21 participants to substance abuse treatment and rehabilitation.
22 (c) The Director shall submit the operating procedures, the plan for a community
23 outreach and education program, and the [substance abuse] ADDICTION treatment
24 [linkage] REFERRAL protocol to the Commissioner of Health OR THE COMMISSIONER’S
25 DESIGNEE for approval prior to THE implementation OF REVISED PROCEDURES.
26 24–806.
27 (a) The Baltimore City Health Department shall include in its Program operating
28 procedures measures to collect the following data:
29 (1) The number of participants served by the Program;
HOUSE BILL 1502 5
1 (2) The length of time a participant is served by the Program;
2 (3) Demographic profiles of participants served by the Program that
3 include:
4 (i) Age;
5 (ii) Sex;
6 (iii) Race; AND
7 [(iv) Occupation;]
8 [(v)] (IV) Zip code of residence;
9 [(vi) Types of drugs used;
10 (vii) Length of drug use; and
11 (viii) Frequency of injection;]
12 (4) The number of hypodermic needles and syringes exchanged;
13 (5) The number of participants [entering drug counseling and] REFERRED
14 TO ADDICTION treatment; and
15 (6) The number of referrals made by the Program for [drug counseling and]
16 ADDICTION treatment FOR PEOPLE WHO INJECT DRUGS.
17 (b) With the advice [and approval] of the oversight committee, the Baltimore City
18 Health Department shall develop and implement a plan for Program evaluation that shall
19 include the following issues:
20 (1) The ESTIMATED prevalence AND INCIDENCE of HIV among Program
21 participants;
22 [(2) Changes in the level of drug use among Program participants;
23 (3) Changes in the level of needle–sharing among Program participants;
24 (4) Changes in the use of condoms among Program participants;
25 (5) The status of treatment and recovery for Program participants who
26 entered drug treatment programs;
6 HOUSE BILL 1502
1 (6) The impact of the Program on risk behaviors for the transmission of the
2 HIV infection, the hepatitis B virus, and other life–threatening blood–borne diseases
3 among injecting drug users;
4 (7) The cost–effectiveness of the Program versus the direct and indirect
5 costs of the HIV infection in terms of medical treatment and other services normally
6 required by HIV–infected individuals;]
7 [(8)] (2) The strengths and weaknesses of the Program; and
8 [(9)] (3) The advisability of continuing the Program.
9 (c) As part of its plans for data collection and Program evaluation described under
10 subsections (a) and (b) of this section, the Baltimore City Health Department shall develop
11 and implement a methodology[:
12 (1) For identifying Program hypodermic needles and syringes, such as
13 through the use of bar coding or any other method approved by the oversight committee;
14 and
15 (2) To perform HIV antibody testing on the residue left in a sample of
16 hypodermic needles and syringes returned to the Program] TO COLLECT RETURNED
17 NEEDLES AND SYRINGES AND SEND THEM TO THE RAPID ANALYSIS OF DRUGS
18 PROGRAM OPERATED BY THE CENTER FOR HARM REDUCTION AT THE MARYLAND
19 DEPARTMENT OF HEALTH.
20 (d) On or before December 31 of each year, the Baltimore City Health Department
21 shall report to the oversight committee, the Governor, and, in accordance with § 2–1257 of
22 the State Government Article, the General Assembly, on the number of hypodermic needles
23 and syringes exchanged as part of the Program.
24 24–808.
25 [(a)] No Program staff member or Program participant may be found guilty of
26 violating § 5–601, § 5–619, § 5–620, § 5–902, or § 5–904 of the Criminal Law Article for
27 possessing or distributing controlled paraphernalia or drug paraphernalia whenever the
28 possession or distribution of the controlled paraphernalia or drug paraphernalia is a direct
29 result of the employee’s or participant’s activities in connection with the work of the
30 Program authorized under this subtitle.
31 [(b) Notwithstanding the provisions of subsection (a) of this section, a Program
32 staff member or Program participant is not immune from criminal prosecution for:
33 (1) The redistribution of hypodermic needles or syringes in any form;
34 (2) Any activities not authorized or approved by the Program; or
HOUSE BILL 1502 7
1 (3) The possession or distribution of controlled paraphernalia or drug
2 paraphernalia or any other unlawful activity outside of the Baltimore City limits.]
3 24–809.
4 Except for violations of any laws that could arise from residue attached to or
5 contained within hypodermic needles or syringes being returned or already returned to the
6 Program, [nothing in] this subtitle [provides] DOES NOT PROVIDE immunity to a Program
7 staff member or Program participant from criminal prosecution for a violation of any law
8 prohibiting or regulating the use, possession, dispensing, distribution, or promotion of
9 [controlled dangerous substances, dangerous drugs, detrimental drugs, or harmful drugs
10 or any conspiracy or attempt to commit any of those offenses] ILLICIT DRUGS.
11 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
12 October 1, 2025.
[DELETED: :CA      5   C A B P F P P t b t H P S S P a t d D r t P a t m a d o t P p a g r t t A P S N a S B  A S  A  ( B  A S  A  (  S T A 2  ( I]
[DELETED:  H   ( “ AS  Sd ]HV[] Et E 2  ( T AS  Sd  E]HV[] Pt E  ( T   ( Pe f] p s ;   ( O a 2  T   ( B m lg  te[ r cf h a sf  n o h n a s i cE A A I E ECH   h   ( B a as  ;   ( I d u a a s t i p c P r   ( P c tn;H     ( P a l fr r t d c a t s t]
[DELETED: H 3   ( E d in HV HHR n ue    ( I P   ( Eh p f i P]M pe;   ( E ms 2  ( T P  ( T   ( T rs f a w]N R se    ( Ot, os;   ( O]   () T rs f t]()[] N R Mh,t oh;   () O](   () O AS ]()[]H   () O de ]()[    () O](   () U t t o i w t M o B]() Cy d t b a fBCHA I E E a]
[DELETED:  H   ( T   ( P o :    ( P o p f t f      ( A    ( A p f p ae f P p se     ( A   ( P t p 2  ( T  ( W al  d :   ( P fg   e   ( A   ( A p f p a le f PR p  ( T o a e p a t s ae tA]C le LO ORSET O   i . 2  ( T p   ( T]
[DELETED: H 5   ( T   ( D p o p s b t P t i    ( A    ( S    ( R    ( O]    () Z](I    ( T    ( L    ( F   ( T   ( T eOA      ( T dNF   .  ( W al  H i   ( T p   A p   ( C   ( C   ( C   ( T s o t a r f P p w e]
[DELETED:  H    ( T H i t h B v a o l b d a   ( T c o t H i i t o m t a o s n r   () T](   () T](  ( A s ay:   ( F i P h n a s s a t a   ( T p H a t o t r l i a s o h n a s r t t PT C R A S A S T T T A N O RA E A E AHRH E   ( O s t a 2  () N P s m o P p m b f g o v p p r o t e o p a i c w t w o t P  ( N s   ( T   ( A]
[DELETED: H 7   ( T p o d o c p o d p 2  E f v o a l t c a f r a t o c P nn  ps ][ s p o r t u p d d o p o c os.  S A B I F E T t A s t e O]


================================================================================

Raw Text:
HOUSE BILL 1502
J1 5lr3585
CF 5lr3586
By: Delegate Wells (By Request – Baltimore City Administration)
Introduced and read first time: February 14, 2025
Assigned to: Rules and Executive Nominations
A BILL ENTITLED
1 AN ACT concerning
2 Baltimore City – AIDS Prevention Sterile Needle and Syringe Exchange Pilot
3 Program – Revisions
4 FOR the purpose of renaming the AIDS Prevention Sterile Needle and Syringe Exchange
5 Pilot Program to be the HIV Prevention Syringe Services Program; altering the
6 duties of the Program, the Director of the Program, and the Baltimore City Health
7 Department regarding the Program; altering the membership and duties of the
8 Program’s oversight committee; altering the immunity provided to Program staff and
9 participants; and generally relating to the AIDS Prevention Sterile Needle and
10 Syringe Exchange Pilot Program.
11 BY repealing and reenacting, without amendments,
12 Article – Health – General
13 Section 24–801(a)
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Health – General
18 Section 24–801(e), 24–802 through 24–806, 24–808, and 24–809
19 Annotated Code of Maryland
20 (2023 Replacement Volume and 2024 Supplement)
21 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
22 That the Laws of Maryland read as follows:
23 Article – Health – General
24 24–801.
25 (a) In this subtitle the following words have the meanings indicated.
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from exist in g l aw . *hb1502*

2 HOUSE BILL 1502
1 (e) “Program” means the [AIDS] HIV Prevention [Sterile Needle and] Syringe
2 [Exchange Pilot] SERVICES Program.
3 24–802.
4 (a) There is an [AIDS] HIV Prevention [Sterile Needle and] Syringe [Exchange
5 Pilot] SERVICES Program in the Baltimore City Health Department.
6 (b) The Program shall:
7 (1) [Provide] DISTRIBUTE SYRINGES AND PROVIDE for the exchange by
8 participants of used hypodermic needles and syringes for sterile hypodermic needles and
9 syringes AS NEEDED; and
10 (2) Operate in accordance with the procedures approved, with the advice
11 and approval of the oversight committee, by the Commissioner of Health.
12 24–803.
13 The Program shall:
14 (1) Be designed and maintained to provide [maximum security of exchange
15 locations and equipment, including] security measures [that may be] AND PROCESSES
16 required to [control the use and dispersal of] SAFELY DISTRIBUTE hypodermic needles
17 and syringes and [security measures that allow for a full accounting of] ACCOUNT FOR the
18 number of hypodermic needles and syringes [in circulation] EXCHANGED AND
19 DISTRIBUTED BY THE BALTIMORE CITY HEALTH DEPARTMENT and the number of
20 hypodermic needles and syringes in storage;
21 (2) Be operated to allow participants to exchange used hypodermic needles
22 and syringes at [any exchange location, if more than one location is] available MOBILE
23 SYRINGE SERVICES SITES;
24 (3) Include appropriate levels of staff expertise in working with injecting
25 drug users and adequate staff training in providing community SERVICE PROVIDER
26 referrals, counseling, and preventive education;
27 (4) Provide for the dissemination of other preventive means for [curtailing
28 the spread of the HIV infection] DECREASING THE RISK OF HIV TRANSMISSION;
29 (5) Provide [a linkage for] referrals to drug counseling and treatment
30 services, and follow–up to those referrals to assure that participants receive the treatment
31 they desire;

HOUSE BILL 1502 3
1 (6) Educate injecting drug users on the [dangers of contracting the HIV
2 infection] RISK OF TRANSMITTING HIV or the hepatitis B virus through HIGH–RISK
3 needle–sharing practices and [unsafe] sexual behaviors;
4 (7) Include policies and procedures for the screening of applicants to the
5 Program in order to preclude noninjecting drug users from participating in the Program;
6 AND
7 (8) [Establish] IMPLEMENT procedures for identifying Program
8 participants that are consistent with the confidentiality provisions of this subtitle[; and
9 (9) Establish a method of identification and authorization for Program staff
10 members who have access to hypodermic needles, syringes, or Program records].
11 24–804.
12 (a) The Mayor of Baltimore City shall appoint an oversight committee for the
13 Program.
14 (b) The oversight committee shall consist of:
15 (1) [Two representatives] ONE REPRESENTATIVE from academia who
16 [specialize] SPECIALIZES in public health issues;
17 (2) One representative from law enforcement[, nominated by the Secretary
18 of Public Safety and Correctional Services];
19 [(3) One representative of the Baltimore City Police Department;]
20 [(4)] (3) [Two representatives] ONE REPRESENTATIVE from the
21 Maryland Department of Health[, the Department of Juvenile Services, or the Department
22 of Education, nominated by the Secretary of Health];
23 [(5)] (4) One representative of a Baltimore City community group;
24 [(6)] (5) One representative of an [AIDS] HIV advocacy group;
25 [(7)] (6) One [drug abuse] ADDICTION treatment counselor;
26 [(8)] (7) One recovering injecting drug user; and
27 [(9)] (8) Up to three other individuals whom the [Mayor of Baltimore
28 City] BALTIMORE CITY HEALTH DEPARTMENT determines to be appropriate for
29 appointment to the oversight committee.

4 HOUSE BILL 1502
1 (c) The oversight committee shall:
2 (1) Provide advice to the Commissioner of Health and the Program Director
3 on developing AND REVISING AS NECESSARY:
4 (i) Program operating procedures for the [furnishing]
5 DISTRIBUTION and exchange of hypodermic needles and syringes to injecting drug users;
6 (ii) A plan for community outreach and education;
7 (iii) A protocol for providing [a linkage] REFERRALS for Program
8 participants to [substance abuse] ADDICTION treatment and rehabilitation; and
9 (iv) A plan for evaluating the Program; and
10 (2) Provide ongoing oversight of the Program and make recommendations
11 to the Program Director or the Commissioner of Health regarding any aspect of Program
12 procedures, operation, or evaluation.
13 24–805.
14 (a) The Commissioner of Health shall appoint a Director for the Program.
15 (b) With the advice [and approval] of the oversight committee, the Director shall
16 develop AND REVISE AS NECESSARY:
17 (1) Program operating procedures for the [furnishing] DISTRIBUTION and
18 exchange of hypodermic needles and syringes to injecting drug users;
19 (2) A community outreach and education program; and
20 (3) A protocol for providing [a linkage] REFERRALS for Program
21 participants to substance abuse treatment and rehabilitation.
22 (c) The Director shall submit the operating procedures, the plan for a community
23 outreach and education program, and the [substance abuse] ADDICTION treatment
24 [linkage] REFERRAL protocol to the Commissioner of Health OR THE COMMISSIONER’S
25 DESIGNEE for approval prior to THE implementation OF REVISED PROCEDURES.
26 24–806.
27 (a) The Baltimore City Health Department shall include in its Program operating
28 procedures measures to collect the following data:
29 (1) The number of participants served by the Program;

HOUSE BILL 1502 5
1 (2) The length of time a participant is served by the Program;
2 (3) Demographic profiles of participants served by the Program that
3 include:
4 (i) Age;
5 (ii) Sex;
6 (iii) Race; AND
7 [(iv) Occupation;]
8 [(v)] (IV) Zip code of residence;
9 [(vi) Types of drugs used;
10 (vii) Length of drug use; and
11 (viii) Frequency of injection;]
12 (4) The number of hypodermic needles and syringes exchanged;
13 (5) The number of participants [entering drug counseling and] REFERRED
14 TO ADDICTION treatment; and
15 (6) The number of referrals made by the Program for [drug counseling and]
16 ADDICTION treatment FOR PEOPLE WHO INJECT DRUGS.
17 (b) With the advice [and approval] of the oversight committee, the Baltimore City
18 Health Department shall develop and implement a plan for Program evaluation that shall
19 include the following issues:
20 (1) The ESTIMATED prevalence AND INCIDENCE of HIV among Program
21 participants;
22 [(2) Changes in the level of drug use among Program participants;
23 (3) Changes in the level of needle–sharing among Program participants;
24 (4) Changes in the use of condoms among Program participants;
25 (5) The status of treatment and recovery for Program participants who
26 entered drug treatment programs;

6 HOUSE BILL 1502
1 (6) The impact of the Program on risk behaviors for the transmission of the
2 HIV infection, the hepatitis B virus, and other life–threatening blood–borne diseases
3 among injecting drug users;
4 (7) The cost–effectiveness of the Program versus the direct and indirect
5 costs of the HIV infection in terms of medical treatment and other services normally
6 required by HIV–infected individuals;]
7 [(8)] (2) The strengths and weaknesses of the Program; and
8 [(9)] (3) The advisability of continuing the Program.
9 (c) As part of its plans for data collection and Program evaluation described under
10 subsections (a) and (b) of this section, the Baltimore City Health Department shall develop
11 and implement a methodology[:
12 (1) For identifying Program hypodermic needles and syringes, such as
13 through the use of bar coding or any other method approved by the oversight committee;
14 and
15 (2) To perform HIV antibody testing on the residue left in a sample of
16 hypodermic needles and syringes returned to the Program] TO COLLECT RETURNED
17 NEEDLES AND SYRINGES AND SEND THEM TO THE RAPID ANALYSIS OF DRUGS
18 PROGRAM OPERATED BY THE CENTER FOR HARM REDUCTION AT THE MARYLAND
19 DEPARTMENT OF HEALTH.
20 (d) On or before December 31 of each year, the Baltimore City Health Department
21 shall report to the oversight committee, the Governor, and, in accordance with § 2–1257 of
22 the State Government Article, the General Assembly, on the number of hypodermic needles
23 and syringes exchanged as part of the Program.
24 24–808.
25 [(a)] No Program staff member or Program participant may be found guilty of
26 violating § 5–601, § 5–619, § 5–620, § 5–902, or § 5–904 of the Criminal Law Article for
27 possessing or distributing controlled paraphernalia or drug paraphernalia whenever the
28 possession or distribution of the controlled paraphernalia or drug paraphernalia is a direct
29 result of the employee’s or participant’s activities in connection with the work of the
30 Program authorized under this subtitle.
31 [(b) Notwithstanding the provisions of subsection (a) of this section, a Program
32 staff member or Program participant is not immune from criminal prosecution for:
33 (1) The redistribution of hypodermic needles or syringes in any form;
34 (2) Any activities not authorized or approved by the Program; or

HOUSE BILL 1502 7
1 (3) The possession or distribution of controlled paraphernalia or drug
2 paraphernalia or any other unlawful activity outside of the Baltimore City limits.]
3 24–809.
4 Except for violations of any laws that could arise from residue attached to or
5 contained within hypodermic needles or syringes being returned or already returned to the
6 Program, [nothing in] this subtitle [provides] DOES NOT PROVIDE immunity to a Program
7 staff member or Program participant from criminal prosecution for a violation of any law
8 prohibiting or regulating the use, possession, dispensing, distribution, or promotion of
9 [controlled dangerous substances, dangerous drugs, detrimental drugs, or harmful drugs
10 or any conspiracy or attempt to commit any of those offenses] ILLICIT DRUGS.
11 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
12 October 1, 2025.

[DELETED: :CA      5   C A B P F P P t b t H P S S P a t d D r t P a t m a d o t P p a g r t t A P S N a S B  A S  A  ( B  A S  A  (  S T A 2  ( I]
[DELETED:  H   ( “ AS  Sd ]HV[] Et E 2  ( T AS  Sd  E]HV[] Pt E  ( T   ( Pe f] p s ;   ( O a 2  T   ( B m lg  te[ r cf h a sf  n o h n a s i cE A A I E ECH   h   ( B a as  ;   ( I d u a a s t i p c P r   ( P c tn;H     ( P a l fr r t d c a t s t]
[DELETED: H 3   ( E d in HV HHR n ue    ( I P   ( Eh p f i P]M pe;   ( E ms 2  ( T P  ( T   ( T rs f a w]N R se    ( Ot, os;   ( O]   () T rs f t]()[] N R Mh,t oh;   () O](   () O AS ]()[]H   () O de ]()[    () O](   () U t t o i w t M o B]() Cy d t b a fBCHA I E E a]
[DELETED:  H   ( T   ( P o :    ( P o p f t f      ( A    ( A p f p ae f P p se     ( A   ( P t p 2  ( T  ( W al  d :   ( P fg   e   ( A   ( A p f p a le f PR p  ( T o a e p a t s ae tA]C le LO ORSET O   i . 2  ( T p   ( T]
[DELETED: H 5   ( T   ( D p o p s b t P t i    ( A    ( S    ( R    ( O]    () Z](I    ( T    ( L    ( F   ( T   ( T eOA      ( T dNF   .  ( W al  H i   ( T p   A p   ( C   ( C   ( C   ( T s o t a r f P p w e]
[DELETED:  H    ( T H i t h B v a o l b d a   ( T c o t H i i t o m t a o s n r   () T](   () T](  ( A s ay:   ( F i P h n a s s a t a   ( T p H a t o t r l i a s o h n a s r t t PT C R A S A S T T T A N O RA E A E AHRH E   ( O s t a 2  () N P s m o P p m b f g o v p p r o t e o p a i c w t w o t P  ( N s   ( T   ( A]
[DELETED: H 7   ( T p o d o c p o d p 2  E f v o a l t c a f r a t o c P nn  ps ][ s p o r t u p d d o p o c os.  S A B I F E T t A s t e O]